Effect of Afatinib for Lung Cancer on Papillary Thyroid Carcinoma
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Papillary thyroid carcinoma is the most common type of thyroid cancer, for which surgery following preoperative staging and risk assessment is the standard treatment. Afatinib is an orally active irreversible ErbB-family inhibitor that binds to the kinase domain of epidermal growth factor receptors (EGFRs), HER2, and HER4, and has been approved as monotherapy for the treatment of locally advanced or metastatic non-small cell lung cancer with activated EGFR mutations. Recently, we observed an unexpected effect of afatinib administered to treat lung cancer on untreated papillary thyroid carcinoma.
Abstract
Papillary thyroid carcinoma is the most common type of thyroid cancer, for which surgery following preoperative staging and risk assessment is the standard treatment. Afatinib is an orally active irreversible ErbB-family inhibitor that binds to the kinase domain of epidermal growth factor receptors (EGFRs), HER2, and HER4, and has been approved as monotherapy for the treatment of locally advanced or metastatic non-small cell lung cancer with activated EGFR mutations. Recently, we observed an unexpected effect of afatinib administered to treat lung cancer on untreated papillary thyroid carcinoma.
참고문헌 (8)
- Annual report of cancer statistics in Korea in 2019, "Korea Central Cancer Registry", 66~ (2021)
- Haugen BR, "2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer : the American Thyroid Association guidelines task force on thyroid nodules and differentiated thyroid cancer", Thyroid, 26(1), pp.1~133 (2016)
- Wind S, "Clinical pharmacokinetics and pharmacodynamics of afatinib", Clin Pharmacokinet, 56(3), pp.235~250 (2017)
- Keating GM, "Afatinib : a review of its use in the treatment of advanced non-small cell lung cancer", Drugs, 74(2), pp.207~221 (2014)
- Fallahi P, "New therapies for dedifferentiated papillary thyroid cancer", Int J Mol Sci, 16(3), pp.6153~6182 (2015)
- Zhang H, "Identification of differentially expressed kinase and screening potential anticancer drugs in papillary thyroid carcinoma", Dis Markers, 2016, pp.2832980~ (2016)
- Dai Y-J, "Concomitant high expression of ERα36, EGFR and HER2is associated with aggressive behaviors of papillary thyroid carcinomas", Sci Rep, 7(1), pp.12279~ (2017)
- Tang C, "High expression of GPER1, EGFR and CXCR1 is associated with lymph node metastasis in papillary thyroid carcinoma", Int J Clin Exp Pathol, 7(6), pp.3213~3223 (2014)